EA201790779A1 - Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений - Google Patents
Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединенийInfo
- Publication number
- EA201790779A1 EA201790779A1 EA201790779A EA201790779A EA201790779A1 EA 201790779 A1 EA201790779 A1 EA 201790779A1 EA 201790779 A EA201790779 A EA 201790779A EA 201790779 A EA201790779 A EA 201790779A EA 201790779 A1 EA201790779 A1 EA 201790779A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- treatment
- methods
- compositions
- aminopurin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 | |
| PCT/US2015/053941 WO2016057370A1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201790779A1 true EA201790779A1 (ru) | 2017-09-29 |
Family
ID=55632334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790779A EA201790779A1 (ru) | 2014-10-06 | 2015-10-05 | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (OSRAM) |
| EP (2) | EP3204386B1 (OSRAM) |
| JP (4) | JP6884701B2 (OSRAM) |
| KR (2) | KR102504849B1 (OSRAM) |
| CN (2) | CN113248506A (OSRAM) |
| AR (2) | AR102171A1 (OSRAM) |
| AU (2) | AU2015328414B2 (OSRAM) |
| CA (1) | CA2963639C (OSRAM) |
| CL (1) | CL2017000820A1 (OSRAM) |
| CO (1) | CO2017003838A2 (OSRAM) |
| CY (1) | CY1124173T1 (OSRAM) |
| DK (1) | DK3204386T3 (OSRAM) |
| EA (1) | EA201790779A1 (OSRAM) |
| EC (1) | ECSP17026210A (OSRAM) |
| ES (2) | ES2871142T3 (OSRAM) |
| HR (1) | HRP20210656T1 (OSRAM) |
| HU (1) | HUE054694T2 (OSRAM) |
| IL (2) | IL251566B (OSRAM) |
| LT (1) | LT3204386T (OSRAM) |
| MX (2) | MX388321B (OSRAM) |
| PL (1) | PL3204386T3 (OSRAM) |
| PT (1) | PT3204386T (OSRAM) |
| RS (1) | RS61884B1 (OSRAM) |
| SG (2) | SG10202009598VA (OSRAM) |
| SI (1) | SI3204386T1 (OSRAM) |
| SM (1) | SMT202100302T1 (OSRAM) |
| TW (1) | TW201629063A (OSRAM) |
| WO (1) | WO2016057370A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113248506A (zh) * | 2014-10-06 | 2021-08-13 | 西格诺药品有限公司 | 取代的氨基嘌呤化合物、其组合物及其治疗方法 |
| WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| EA032315B1 (ru) | 2015-03-18 | 2019-05-31 | Бристол-Маерс Сквибб Компани | Замещенные трициклические гетероциклические соединения |
| ES2797685T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF |
| KR102696304B1 (ko) | 2015-03-18 | 2024-08-16 | 브리스톨-마이어스 스큅 컴퍼니 | Tnf의 억제제로서 유용한 헤테로시클릭 화합물 |
| CN107922287B (zh) | 2015-07-24 | 2021-04-09 | 细胞基因公司 | 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体 |
| CN108137609B (zh) | 2015-08-03 | 2021-07-16 | 百时美施贵宝公司 | 用作TNFα的调节剂的环状化合物 |
| CN109069512B (zh) * | 2016-04-01 | 2022-06-14 | 西格诺药品有限公司 | 取代的氨基嘌呤化合物、其组合物以及相关治疗方法 |
| PT3436019T (pt) * | 2016-04-01 | 2021-11-04 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos |
| WO2017210399A1 (en) * | 2016-06-02 | 2017-12-07 | Celgene Corporation | Animal and human anti-malarial agents |
| CN109476696B (zh) * | 2016-06-02 | 2022-06-10 | 细胞基因公司 | 动物及人抗锥虫和抗利什曼原虫剂 |
| CN111432841A (zh) | 2017-10-04 | 2020-07-17 | 细胞基因公司 | 顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的组合物和使用方法 |
| US10590136B2 (en) | 2017-10-04 | 2020-03-17 | Celgene Corporation | Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| EP1951693A4 (en) | 2005-11-18 | 2012-05-30 | Astrazeneca Ab | SOLID FORMULATIONS |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| NZ589053A (en) | 2006-10-27 | 2012-03-30 | Signal Pharm Llc | Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| ES2400006T3 (es) | 2008-04-23 | 2013-04-04 | Farmasierra Manufacturing, S.L. | Formulación farmacéutica mejorada a base de ibuprofeno y codeína |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| CN113248506A (zh) | 2014-10-06 | 2021-08-13 | 西格诺药品有限公司 | 取代的氨基嘌呤化合物、其组合物及其治疗方法 |
| PT3436019T (pt) | 2016-04-01 | 2021-11-04 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos |
-
2015
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201790595A1 (ru) | Пиримидиноны в качестве ингибиторов фактора xia | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| EA201992370A1 (ru) | Соединения и способы для лечения бактериальных инфекций | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| EA201792676A1 (ru) | Ингибиторы jak1 | |
| EA201992557A1 (ru) | Противоопухолевые соединения |